Community Practice

Here’s a roundup of the latest coronavirus-related news from this week. 

Officials with the FDA have granted approval to ozanimod (Zeposia, Bristol Myers Squibb) for the treatment of relapsing multiple sclerosis.

Health care providers should look out for more than just respiratory diagnoses in patients when it comes to influenza-associated complications, according to a recent study. 

In a joint statement, the American Medical Association (AMA), American Pharmacists Association (APhA), and American Society of Health-System Pharmacists (ASHP) have communicated concerns regarding the inappropriate ordering, prescribing, or dispensing of treatments for COVID-19.

CVS Caremark’s new quantity limits will not affect members who are already receiving these medications for their approved uses.

Crisaborole ointment, 2% (Eucrisa, Pfizer) has been approved for use in pediatric patients with atopic dermatitis as young as 3 months of age.

The announcement follows their previous commitment to offering COVID-19 testing at local hospitals.

Due to the increased need for albuterol inhalers in hospitals for COVID-19, shortages have been occurring in some areas of the country and will likely continue to affect supplies.

The updated labeling recommends temporary discontinuation of SGLT2 inhibitors before scheduled surgery.

There is currently no scientific evidence suggesting that non-steroidal anti-inflammatory drug use could worsen COVID-19 in those infected.

What new gaps will pharmacists need to fill?

It’s my hope that 2020 is a profession changing year, starting with the schools of pharmacy.

Genentech is launching a phase 3 clinical trial evaluating tocilizumab (Actemra) plus standard of care for use in hospitalized adult patients with severe COVID-19 pneumonia.

Perspectives from pharmacy associations in the states hardest hit with the COVID-19 outbreak.

A CDC analysis of preliminary data suggests that COVID-19 complications can occur in adults of any age.

Analysts have forecasted the market for NASH drugs could reach $20 billion by 2025.

We asked pharmacists from various settings around the country: “Why did you become a pharmacist, and what keeps you motivated?"

From drug information to patient education, these apps can help you be better at everything that you do.

Dr. Reddy’s Laboratories has launched its ziprasidone mesylate 20 mg/mL for injection, the first generic version of Geodon (Pfizer) for injection. 

A study evaluated the stability of COVID-19 compared with SARS-CoV-1.

When looking to grow business with supplement sales, pharmacists should first educate themselves.

Relieving symptoms and optimizing therapies for allergic rhinitis

President Trump's coronavirus task force urged to tap into the potential of community pharmacies in combatting the coronavirus pandemic. 

Pharmacy managers and educators offer career advice.

On December 23, 2019, the FDA approved ubrogepant for the acute treatment of migraine with and without aura in adult patients.

Insurers, physicians, and others are advising patients with chronic conditions to ensure they have more than enough medication on hand. 

A new study identified demographics that characterize a higher risk of conscientious vaccination exemptions for children in Texas.

Empagliflozin (Jardiance, Eli Lilly and Boehringer Ingelheim) is being investigated to reduce the risk of kidney disease progression and cardiovascular death in adults with chronic kidney disease.

Approximately 1 million individuals are living with multiple sclerosis in the United States, according to the National MS Society.

Walgreens, CVS Health, and Target said they will start providing coronavirus disease (COVID-19) testing in their parking lots.